Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 4/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | Q9HBH1 | 1/20 | 0.34 | |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13110590 | 0.94 | HTR2A (0.40) | FURINMAP1LC3BHTR2ASSTR3PTPN1 | |
| SCHEMBL29414597 | 0.94 | HTR2A (0.40) | FURINMAP1LC3BHTR2ASSTR3PTPN1 | |
| SCHEMBL12944195 | 0.94 | HTR2A (0.40) | FURINMAP1LC3BHTR2ASSTR3PTPN1 | |
| SCHEMBL29579452 | 0.94 | HTR2A (0.40) | FURINMAP1LC3BHTR2ASSTR3PTPN1 | |
| SCHEMBL19731720 | 0.94 | HTR2A (0.40) | FURINMAP1LC3BHTR2ASSTR3PTPN1 | |
| SCHEMBL12094377 | 0.94 | HTR2A (0.40) | FURINMAP1LC3BHTR2ASSTR3PTPN1 | |
| SCHEMBL13830646 | 0.94 | HTR2A (0.40) | FURINMAP1LC3BHTR2ASSTR3PTPN1 | |
| SCHEMBL2734925 | 0.94 | HTR2A (0.40) | FURINMAP1LC3BHTR2ASSTR3PTPN1 | |
| SCHEMBL16712824 | 0.93 | HTR2A (0.38) | HTR2ASSTR3PTPN1SIRT2SIRT1 | |
| SCHEMBL15691954 | 0.93 | KMT2A (0.38) | FURINMAP1LC3BHTR2ASSTR3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281630-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | TORAY INDUSTRIES, INC. (JP) | 2025-09-11 | — | — | US | disclosed |
| EP-4400121-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20230398232-A1 | Composition and Use of Alternatively Formatted Anti-Mesothelin Antibodies for the Treatment of Cancer | Navrogen, Inc. | 2023-12-14 | — | — | US | disclosed |
| EP-4217009-A1 | COMPOSITION AND USE OF ALTERNATIVELY FORMATTED ANTI-MESOTHELIN ANTIBODIES FOR THE TREATMENT OF CANCER | Navrogen, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116390733-A | Compositions and uses of alternative formatted anti-mesothelin antibodies for the treatment of cancer | 纳夫罗根公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023033129-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | 東レ株式会社 | 2023-03-09 | — | — | WO | disclosed |
| WO-2022067224-A1 | COMPOSITION AND USE OF ALTERNATIVELY FORMATTED ANTI-MESOTHELIN ANTIBODIES FOR THE TREATMENT OF CANCER | Navrogen, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |